AlphAIAlphAI — Financial news for AI agents
investing.com$ZTS

Why is Zoetis stock climbing today?

Zoetis (ZTS) stock rose 2.4% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.75 vs. $1.51 and revenue of $2.4B vs. $2.3B. The company raised full-year EPS guidance to $6.25–$6.35. International sales grew 4%, while U.S. companion animal business faced challenges. The stock traded near $91.30 premarket, below its 52-week high of $132.49.

Original reporting
investing.com
Published Nov 5, 2026, 1:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ZTS
Bullish
high confidence
Mentioned
$ZTS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ZTSBullishHigh
01

Why it matters

The earnings beat and guidance raise suggest stronger demand across livestock and diagnostics, offsetting softness in companion animals.

02

Market read

Zoetis' strong earnings and raised outlook are likely to drive short‑term buying pressure and may lift related animal health stocks.

03

What to watch

Potential headwinds in U.S. companion animal pricing and competitive dermatology pressures.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Zoetis is the world’s leading animal health company; its earnings are closely watched by healthcare investors.

Company-level read

Ticker impact

$ZTSBullishHigh confidence
Context

Zoetis reported Q3 2026 earnings beating estimates and raised full-year EPS guidance, driving a 2.4% pre‑market price rise.

Expected impact

likely upward pressure as investors price in stronger earnings and higher guidance

Evidence & confidence

The beat was sizable ($0.24 EPS beat) and guidance was lifted above consensus, which typically fuels buying.

Market effects

Sector

Animal health sector may see broader rally as Zoetis outperforms expectations.

Regional

U.S. markets likely gain modestly from the positive earnings news.

Global

Limited to investors focused on healthcare and animal health stocks.

Counterpoint

What could challenge this read

If guidance is overly optimistic, the stock could face a pull‑back once detailed forecasts are released.

Key entities

  • Company
    Zoetis Inc.

    Animal health company reporting Q3 2026 results.

  • Executive
    Kristin Peck

    CEO of Zoetis who commented on the results.

Read at source← All news

StoryZoetis reports Q3 2026 results, beats EPS and raises full‑year guidance

Also covered by

5 outlets

Related articles

$ZTSMedAI 8/10

Zoetis (ZTS) Q3 2026 Earnings Call Transcript

Zoetis (ZTS) reported Q3 2026 earnings with revenue and adjusted net income declining as expected. The company cited challenges in pet care due to rising costs and changing pet ownership trends, while livestock demand remains strong. Zoetis narrowed its full-year revenue guidance to the high end of its range and highlighted investments in key franchises and innovation.

finance.yahoo.com
$ZTSMedAI 8/10

Zoetis 3Q 2026: Revenue $2.39B, EPS $1.44 — 10-Q Summary

Zoetis reported 3Q 2026 revenue of $2.39B, down 1% YoY, and net income of $1.44B, down 18%. Declines were driven by softer U.S. companion-animal demand, competition, and lower prices, partially offset by livestock growth and favorable exchange rates. Higher restructuring costs also impacted earnings. U.S. companion-animal revenue fell 8%, while U.S. livestock and international revenues rose 5% and 4%, respectively.

tradingview.com